Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
TypePublic
HQWarren, US
Founded2009
Size (employees)22 (est)
Websitebellerophon.com
Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Bellerophon Therapeutics Office Locations

Bellerophon Therapeutics has an office in Warren
Warren, US (HQ)
302 184 Liberty Corner Rd
Show all (1)
Report incorrect company information

Bellerophon Therapeutics Financials and Metrics

Bellerophon Therapeutics Revenue

USD

Net income (Q2, 2018)

(7.4 m)

EBIT (Q2, 2018)

(16.4 m)

Market capitalization (20-Sep-2018)

67 m

Closing stock price (20-Sep-2018)

1.2

Cash (30-Jun-2018)

23.4 m
Bellerophon Therapeutics's current market capitalization is $67 m.
Annual
USDFY, 2016

General and administrative expense

2.2 m

R&D expense

5.1 m

Operating expense total

7.3 m

EBIT

(7.3 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

General and administrative expense

4.6 m3.4 m4.3 m2 m1.2 m1.7 m1.4 m2.1 m4.2 m

R&D expense

9.5 m8.4 m7.1 m5.1 m4 m2.5 m3.3 m6.4 m12.2 m

Operating expense total

14.1 m11.9 m11.4 m7.1 m5.2 m4.2 m4.8 m8.5 m16.4 m

EBIT

(12.9 m)(11.6 m)(11.2 m)(7.1 m)(5.2 m)(4.2 m)(4.8 m)(8.5 m)(16.4 m)
Annual
USDFY, 2016

Cash

14.5 m

Current Assets

26.5 m

PP&E

1.4 m

Total Assets

29.7 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Cash

62.9 m48.5 m23.9 m1.3 m1.3 m3.9 m13.5 m28.4 m23.4 m

Current Assets

73.6 m60.9 m46.9 m23.1 m18.6 m17.5 m23.2 m34.8 m28.8 m

PP&E

1.6 m1.5 m1.8 m1.7 m1.6 m1.5 m1.3 m935 k845 k

Total Assets

75.2 m62.4 m49.2 m31.2 m26.3 m22.8 m25.8 m35.9 m29.8 m
Annual
USDFY, 2016

Net Income

(23.8 m)

Depreciation and Amortization

(400 k)

Cash From Operating Activities

(17.2 m)

Cash From Investing Activities

12.2 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(12.9 m)(11.6 m)(11.1 m)(7.1 m)(5.1 m)(4.2 m)(19.1 m)4.1 m(7.4 m)

Depreciation and Amortization

91 k181 k

Accounts Payable

659 k966 k934 k641 k2 m2.2 m3.9 m

Cash From Operating Activities

(444 k)(6.1 m)
USDY, 2018

Financial Leverage

-3.8 x
Show all financial metrics
Report incorrect company information

Bellerophon Therapeutics Company Life and Culture

Report incorrect company information